AB Science S.A.

AB Science S.A.

ABSCF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$82.04M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
AB Science S.A.AB Science S.A.-7.8-62%--0.2
$-0.06

Current Fair Value

105.7% downside

Overvalued by 105.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$82.04 Million
Enterprise Value$77.80 Million
Earnings per Share$-0.03
Beta1.24
Outstanding Shares67,826,080

Return

Return on Equity61.81%ROE
Return on Assets-76.72%
Return on Invested Capital-531.27%

Valuation & Multiples

P/E Ratio-7.76P/E Ratio
PEG-10.63PEG
Price to Sales-Price to Sales
Price to Book Ratio-1.12Price to Book Ratio
Enterprise Value to Revenue35.69
Enterprise Value to EBIT-5.29
Enterprise Value to Net Income-6
Total Debt to Enterprise0.06
Debt to Equity-0.21Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 9, 2026
EPS
-$0.15
Est. -$0.08
Revenue
$568,746
Est. $685,236

Next Earnings Call

Expected Date
April 23, 2027
EPS Estimate
-$0.08
Consensus analyst estimate
Revenue Estimate
$658,332
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About AB Science S.A.

40 employees
CEO: Stéphane Ledermann

AB Science S.A. is a pharmaceutical firm focused on discovering, advancing, and commercializing protein kinase inhibitors for both human and animal therapeutic applications. The company's primary drug candidate, masitinib, a tyrosine kin...